Apollo Neuro Raises $15Million Series A to Elevate the First Wellness Wearable That Actively Improves Mental Health

Round Led by Noetic Fund to Accelerate Growth as Category Leader in Wearable Stress Relief Technology

Apollo Neuro, makers of the first scientifically validated wearable that improves the body’s resilience to stress, announced it has raised $15 million in Series A funding at a valuation over $100 million to empower people to take control of their mental health and well-being.

“Apollo Neuro’s touch technology represents an entirely new way to think about wearables”

Led by Noetic Fund, the funding will help Apollo Neuro reach new global users who want to feel like a healthier, better version of themselves. Distinctively unique when compared to other wellness wearables that solely track health metrics, Apollo’s patented stress-relieving technology actively helps the body recover quickly, enabling better sleep, relaxation, and focus. Currently the Apollo wearable is available for a one time purchase ($349) in the United States, Canada, Europe and Australia/New Zealand, and pairs with a mobile app to help you transition throughout the day.

Download Our Top Whitepaper : Building Reliable and Secure Fintech Systems in 2022

What is the Apollo wearable?

Apollo is a wellness wearable that improves your body’s resilience to stress, so you can relax, sleep, focus, recover, and feel better. Worn on either the wrist or ankle, the Apollo device works by engaging with your sense of touch, delivering silent, soothing vibrations that help you feel safe and in control. Apollo Neuro’s scientifically validated technology trains your nervous system to bounce back from stress more quickly, going from “fight or flight” to “rest and digest.”

Preliminary results from an ongoing sleep study (launched in 2021) showcase how the Apollo wearable improves the quality of sleep, along with important cardiovascular metrics including heart rate variability (HRV), a key metric of the body’s recovery from and resilience to stress. The real-world study, featuring more than 500 participants, found that Apollo wearers experience, on average:

• 19% increase in deep sleep
• 14% increase in REM sleep
• 5% lower resting heart rate
• 11% average increase in heart rate variability (HRV)

“We are thrilled to announce the closing of our Series A, affording us the opportunity to rapidly accelerate advancements in consumer health with the Apollo wearable,” said Dr. David Rabin, Psychiatrist, Neuroscientist, and Co-Founder of Apollo Neuroscience. “Now, two years after bringing our product to market, we find ourselves living in a moment-in-time where Apollo Neuro’s scientifically proven stress-relieving technology is more vital than ever as we strive for more balance in our daily lives.”

Recommended AI News: FSSI Introduces Direct Mail Division to Expand Marketing Services to Clients

Health Improvement, Not Health Tracking

By 2026, the global wearable technology market will exceed $19.12 billion with more than 344.9 million units shipping in 2022 alone. The Apollo wearable distinguishes itself in the category by showcasing the ability to improve health, while other wearable devices simply track health and data.

“Apollo Neuro’s touch technology represents an entirely new way to think about wearables,” said Co-Founder and CEO, Kathryn Fantauzzi. “Rather than tracking, Apollo Neuro’s gentle vibrations let us take control over how we feel so that we can focus, relax, get deep restorative sleep, or socialize. Now, with our Series A closed, we’re geared up and ready to deliver new ways to experience Apollo Neuro. I’m excited to show what’s possible when you tap into the sense of touch to enable us all to choose how we feel and experience the world around us.”

Developed by neuroscientists and physicians, the Apollo wearable is a safe, non-invasive stress relief tool for adults and children, without side effects. The Apollo device is a tool for mental health care and beneficial for anyone looking to incorporate active stress-relieving technology into their daily lives, from expectant moms to veterans to high-performance athletes to first responders, all of whom can benefit from consistent use.

Across the research, Apollo users (on average) experienced:

• 40% less stress and feelings of anxiety
• 30 more minutes of sleep
• 50% more energy
• Up to 25% more focus and concentration

“At Noetic Fund we invest in innovative therapies that address significant unmet needs within mental health,” said Sa’ad Shah, Co-Founder and Managing Partner at Noetic Fund. “Apollo Neuro represents a truly disruptive and scalable technology that makes managing stress, sleeping well, and keeping a clear mind easier. We’re excited by the potential of the Apollo wearable to complement new therapies, like psychedelic-assisted psychotherapy, and could not be more proud to partner with the Apollo Neuro team to present an accessible technology that is already changing tens of thousands of lives.”

Recommended AI News: Activ Technologies Partners with Munich Team for EMEA Expansion

[To share your insights with us, please write to sghosh@martechseries.com]